Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FISPAC: Autologous ASCs for Complex Perianal Fistula
NCT01803347Phase 3Completed
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Feb 2013
- Primary completion
- Oct 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of autologous adipose-derived mesenchymal stromal cells in anal fistula, sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoint: Fistula Healing Rate at 16 weeks. Started Feb 2013; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
anal fistula
Beyond the preview
Go deeper on NCT01803347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01803347.